{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:30:41Z","timestamp":1789122641977,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Public Health Service","award":["P01AI186818"],"award-info":[{"award-number":["P01AI186818"]}]},{"name":"Public Health Service","award":["R01AI063503"],"award-info":[{"award-number":["R01AI063503"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Fungi","JoF"],"abstract":"<jats:p>Mucormycosis is a highly lethal invasive fungal infection caused by fungi of the order Mucorales, with mortality rates exceeding 50% despite current antifungal therapies with polyenes or azoles. Because iron acquisition is essential for Mucorales growth and virulence, we investigated whether transferrin, the primary physiological iron-sequestering protein in plasma, could serve as a host-directed therapeutic strategy against mucormycosis. Transferrin inhibited the growth of clinically relevant Mucorales species, including Rhizopus delemar (R. delemar), Rhizomucor, and Lichtheimia corymbifera (L. corymbifera) in a concentration-dependent manner. Checkerboard assays demonstrated synergistic interactions between transferrin and liposomal amphotericin B (LAMB), with fractional inhibitory concentration index values below 0.5 for all tested species. In endothelial cell infection model, transferrin significantly reduced expression of the fungal invasion ligand spore coat protein homolog 3 (CotH3) and the host receptor glucose-regulated protein 78 (GRP78), key mediators of angioinvasion during mucormycosis. In a neutropenic murine model of pulmonary mucormycosis, transferrin enhanced the therapeutic efficacy of both LAMB and isavuconazole (ISAV), resulting in improved survival compared with antifungal monotherapy. Collectively, these findings provide preclinical evidence that transferrin modulates pathogenic determinants associated with mucormycosis and enhances the efficacy of current antifungal therapies, supporting further investigation of transferrin as a potential host-directed adjunctive treatment.<\/jats:p>","DOI":"10.3390\/jof12090682","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:09:40Z","timestamp":1789117780000},"page":"682","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8295-7222","authenticated-orcid":false,"given":"Yiyou","family":"Gu","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA 90502, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Teclegiorgis","family":"Gebremariam","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA 90502, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Belal A.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Vitalex Biosciences LLC, Trabuco Canyon, CA 92678, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan","family":"Harb","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA 90502, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA 90502, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-8530","authenticated-orcid":false,"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA 90502, USA"},{"name":"Vitalex Biosciences LLC, Trabuco Canyon, CA 92678, USA"},{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/10428190310001653691","article-title":"Improved outcome of zygomycosis in patients with hematological diseases?","volume":"45","author":"Gleissner","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/422729","article-title":"Zygomycosis: Reemergence of an old pathogen","volume":"39","author":"Kauffman","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/313803","article-title":"Zygomycosis in the 1990s in a tertiary-care cancer center","volume":"30","author":"Kontoyiannis","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/422723","article-title":"Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis","volume":"39","author":"Siwek","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Alqarihi, A., Kontoyiannis, D.P., and Ibrahim, A.S. (2023). Mucormycosis in 2023: An update on pathogenesis and management. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1254919"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/cid\/cir865","article-title":"Pathogenesis of mucormycosis","volume":"54","author":"Ibrahim","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9670007","DOI":"10.26599\/iFungi.2026.9670007","article-title":"Expert Consensus on the Prevention of Secondary Mucormycosis Following Respiratory Viral Infections","volume":"1","author":"Qu","year":"2026","journal-title":"iFungi"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","article-title":"Novel perspectives on mucormycosis: Pathophysiology, presentation, and management","volume":"18","author":"Spellberg","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJMra2412565","article-title":"Mucormycosis","volume":"394","author":"Kontoyiannis","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"You, Z., Zhuang, K., Sugita, T., and Ran, Y. (iFungi, 2026). Novel Strategies Against Fungal Infections: Repurposing Existing Drugs and Advancing Nanotherapeutics, iFungi, in press.","DOI":"10.26599\/iFungi.2026.9670015"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mib.2017.10.010","article-title":"The mucormycete-host interface","volume":"40","author":"Ibrahim","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/1469-0691.12566","article-title":"Mucormycosis\u2014From the pathogens to the disease","volume":"20","author":"Binder","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.mib.2011.07.004","article-title":"Host cell invasion in mucormycosis: Role of iron","volume":"14","author":"Ibrahim","year":"2011","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"a019687","DOI":"10.1101\/cshperspect.a019687","article-title":"Host cell invasion by medically important fungi","volume":"5","author":"Sheppard","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1038\/s41467-018-05820-2","article-title":"Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species","volume":"9","author":"Andrianaki","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1172\/JCI71349","article-title":"CotH3 mediates fungal invasion of host cells during mucormycosis","volume":"124","author":"Gebremariam","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1093\/jac\/dkz225","article-title":"Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria","volume":"74","author":"Luna","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1039\/C6MT00301J","article-title":"Iron acquisition in fungal pathogens of humans","volume":"9","author":"Bairwa","year":"2017","journal-title":"Metallomics"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Smith, C., and Lee, S.C. (2022). Current treatments against mucormycosis and future directions. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010858"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/13693786.2012.669502","article-title":"Risk factors for mortality in patients with mucormycosis","volume":"50","author":"Spellberg","year":"2012","journal-title":"Med. Mycol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/13693780410001731547","article-title":"Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: Comparison of different drug interaction models","volume":"43","author":"Meletiadis","year":"2005","journal-title":"Med. Mycol."},{"key":"ref_24","first-page":"WMC001111","article-title":"Vascular Endothelial Growth Factor Increases Endothelial Nitric Oxide Synthase Transcription in Huvec Cells","volume":"1","author":"Koai","year":"2010","journal-title":"Webmedcentral"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41564-020-00837-0","article-title":"Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis","volume":"6","author":"Soliman","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"eaaw1327","DOI":"10.1126\/sciadv.aaw1327","article-title":"Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis","volume":"5","author":"Gebremariam","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/infdis\/jiu049","article-title":"Transferrin iron starvation therapy for lethal bacterial and fungal infections","volume":"210","author":"Lin","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/CMR.12.3.394","article-title":"Acquisition, transport, and storage of iron by pathogenic fungi","volume":"12","author":"Howard","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkl350","article-title":"Deferiprone iron chelation as a novel therapy for experimental mucormycosis","volume":"58","author":"Ibrahim","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.imbio.2006.02.004","article-title":"Iron-withholding strategy in innate immunity","volume":"211","author":"Ong","year":"2006","journal-title":"Immunobiology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1073\/pnas.1914830117","article-title":"Iron sequestration by transferrin 1 mediates nutritional immunity in Drosophila melanogaster","volume":"117","author":"Iatsenko","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1172\/JCI42164","article-title":"The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice","volume":"120","author":"Liu","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"eads7369","DOI":"10.1126\/scitranslmed.ads7369","article-title":"A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response","volume":"17","author":"Gu","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: A randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.chom.2013.04.010","article-title":"Iron in infection and immunity","volume":"13","author":"Cassat","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.mib.2015.07.005","article-title":"Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections","volume":"27","author":"Bruhn","year":"2015","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Guldiken, N., Argemi, J., Gurbuz, B., Atkinson, S.R., Oliverius, M., Fila, P., Hamesch, K., Bruns, T., Cabezas, J., and Lozano, J.J. (2021). Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases. BMC Med., 19.","DOI":"10.1186\/s12916-021-01917-6"}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/12\/9\/682\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:33:39Z","timestamp":1789119219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/12\/9\/682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jof12090682"],"URL":"https:\/\/doi.org\/10.3390\/jof12090682","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}